# TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

> **NCT04323657** · PHASE1,PHASE2 · COMPLETED · sponsor: **TCR2 Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Non Hodgkin Lymphoma
- Acute Lymphoblastic Leukemia
- Diffuse Large B Cell Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma

## Interventions

- **DRUG:** TC-110 T Cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04323657
- **Lead sponsor:** TCR2 Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-27
- **Primary completion:** 2023-02-24
- **Final completion:** 2023-02-24
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04323657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04323657, "TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04323657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*